Clinical trial NCT02248909: Non-interventional Study of Spirometry Use to Diagnose COPD (Chronic Obstructive Pulmonary Disease) and to Prescribe Treatment to COPD Patients in the Outpatient Institutions
Official title: Non-interventional Multicenter Study of Spirometry Use to Diagnose COPD and to Prescribe Treatment to COPD Patients in the Outpatient Institutions of the healthcaRe System of the Russian FederaTion
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COPD
Keywords: COPD, Primary Care, Spirometry, Risk factors
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2014-09-25
Enrollment: 4232
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with COPD risk factors and patients with previously diagnosed COPD who have been observed in outpatient medical institutions of the RF are planned to be enrolled into the study.

Brief summary: This study is an observational multicenter descriptive study. The study will be conducted in primary outpatient medical institutions in different cities of the RF. Primary care doctors who are primary contact for greater part of the population in RF including COPD patients will be invited as investigators. This observational descriptive study will be conducted within the routine practice of outpatient institutions. Since spirometry is not an integral part of the current all-round clinical practice, only those sites where spirometry test is routinely used in examination of patients with COPD risk factors and when monitoring condition of COPD patients will take part in the study. Thus the decision about spirometry in every study subject will be determined only by the existing treatment approaches.

Detailed description: The study is an observational multicenter descriptive study. No hypothesis is checked in the study.

3000 patients with COPD risk factors are planned to be enrolled into the study (current smokers and former smokers with smoking history of ≥10 pack/years at the age of \>40 years who have respiratory complaints) and 1450 patients previously diagnosed with COPD who contacted the physicians of outpatient institutions during the study (for 3 months) and are currently in remission.

100 patients with COPD risk factors and approximately 50 patients early diagnosed with COPD currently being stable are planned to be enrolled in each site.

Physicians and pulmonologists of the outpatient institutions of the Russian Federation will take part in the study in about 30 sites in 18 cities (a total of 31% of RF population live in the cities).

The observational descriptive study will be conducted within the routine practice of outpatient institutions. Examining and treatment of patients will be performed according to the rules of the routine practice.

Patients will be enrolled into the study as they visit the outpatient institutions for the medical care. The study does not imply any special invitation of COPD patients to the sites for them to be enrolled into the study. Therefore the conditions are made for the study population to reflect the typical visitors of the primary care medical institutions in different RF (Russian Federation) regions. Patients are enrolled into the study regardless the reason for appointment with a doctor. A reason for the appointment can be respiratory complaints as well as any other diseases or certificates and conclusions. To be enrolled into the study the subjects must sign the written Informed Consent Form (ICF) to participate in the study and to use personal data confidentially.

To investigate the role of spirometry in diagnostics and management of the COPD patients, two groups of patients are supposed to be included into the study.

Eligibility criteria: Patients with COPD risk factors must meet all the following inclusion criteria:

1. Age ≥ 40 years.
2. Smoker or former smoker with smoking history of ≥ 10 pack years (patient is considered to be a former smoker in case of smoking cessation for ≥6 months) (the patient smokes or smoked before but then gave up smoking. The obligatory condition: smoking history is ≥10 pack years. It means that the patient smoked a pack per day for 10 years or half a pack for 20 years or 2 packs a day for 5 years).
3. Any complaints judged by the investigator to be possibly related to the respiratory diseases (chronic cough, dyspnea, cough with sputum, feeling of stiffness in the chest) or the evidence of the chronic respiratory diseases (chronic bronchitis in remission, pneumosclerosis) in the medical chart.
4. The patient is expected to have the spirometry test performed in accordance with the current medical practice before inviting him to the study.
5. Patients considered by the investigator to be able to complete themselves questionnaires used in the current study.
6. Signed Patient's Information Sheet and Informed Consent Form.

Patients with previously diagnosed COPD must meet all the following inclusion criteria:

1. Male and female of any age who were diagnosed with COPD before the study starts.
2. Patients whose COPD was not the direct reason for visiting the doctor or COPD patients who have COPD symptoms or signs requiring diagnostic or therapy.
3. Patients judged by the investigator as being capable to complete themselves the questionnaires used in the current study
4. Patient was scheduled to have the spirometry test performed in accordance with the existing medical practice before inviting him/her into the study
5. Signed Patient's Information Sheet and Informed Consent Form.

Exclusion criteria for patients with COPD risk factors:

1. Previously diagnosed chronic obstructive pulmonary disease.
2. Patients diagnosed with asthma, pulmonary tuberculosis, congenital lung abnormality, cystic fibrosis, lung cancer or cancer of the upper respiratory tract, patients who had a lung resection in the past due to pulmonary tuberculosis and other lung surgery, patients with stenosis of the upper respiratory tract, post-tracheotomy patients with the developed fibrotic stenosis of the trachea or post-intubation trachea stenosis, patients with ribs fractures of \<3 weeks, pneumo- and hydrothorax of any etiology.
3. Patients who have contraindications for performing spirometry tests, patients with acute coronary syndrome or unstable circulatory dynamics. Patients who need emergency medical care at the moment of the visit.
4. Participation in any interventional clinical trial within 3 months prior the enrollment into the study and at the moment.

Patients with previously diagnosed COPD must meet all the following inclusion criteria:

1. Patients diagnosed with asthma, pulmonary tuberculosis, congenital lung abnormality, cystic fibrosis, lung cancer or cancer of the upper respiratory tract, patients who had a lung resection in the past due to pulmonary tuberculosis and other lung surgery, patients with stenosis of the upper respiratory tract, post-tracheotomy patients with fibrotic stenosis of the trachea or post-intubation trachea stenosis, patients with rib fractures of \<3 weeks, pneumo- and hydrothorax of any etiology.
2. Active exacerbation of chronic obstructive pulmonary disease at the moment of enrollment into the study.
3. Patients who have contraindications for performing spirometry tests, patients with acute coronary syndrome or unstable hemodynamics. Patients who need emergency medical care at the time of the visit.
4. Participation in any interventional clinical trial within 3 months prior the enrollment into the study and at the moment.

Primary outcomes:
measure: The number of COPD cases first-time identified by the spirometry in relation to the total number of patients who visited the outpatient institutions of the RF during the study
timeFrame: Up to 5 months
measure: Percentage of prescriptions for patients with COPD that correspond to the severity of the condition of the patients according to GOLD classification and GOLD recommendations for the treatment choice
timeFrame: Up to 5 months
measure: Distribution (%) of patients with COPD who contacted the primary care doctors during the study based on bronchial obstruction severity (GOLD 1-4) and classes according to GOLD classification (2014)
timeFrame: Up to 5 months
Secondary outcomes:
measure: The percentage (%) of patients who contact the medical institutions of RF daily can be referred to the group with risk of COPD development
timeFrame: Up to 5 months
measure: Score on SGRQ at 1st Visit in COPD patients receiving monotherapy with inhaled long-acting and super long-acting bronchodilators and in patients who are treated with combined drugs containing inhaled corticosteroids and long-acting β2 agonists
timeFrame: Up to 5 months
measure: Score on САТ at 1st Visit in COPD patients receiving monotherapy with inhaled long-acting and super long-acting bronchodilators and in patients who are treated with combined drugs containing inhaled corticosteroids and long-acting β2 agonists
timeFrame: Up to 5 months
measure: Mean number of puffs of SABA for 24h in COPD patients receiving monotherapy with inhaled long-acting and super long-acting bronchodilators and in patients treated with combined drugs (inhaled corticosteroids and long-acting β2 agonists)
timeFrame: Upto 5 months
measure: The percentage of COPD patients in the routine practice of these medical institutions
timeFrame: Up to 5 months
measure: Health-related economic losses calculated on the basis of the collected data (number of hospitalizations due to COPD exacerbations, calls of emergency service due to COPD, seeking outpatient care due to COPD) for the previous year
timeFrame: Up to 5 months
Other outcomes:
Locations:
city: Barnaul
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Blagoveschensk
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Chelyabinsk
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Cherepovets
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Izhevsk
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Kazan
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Kemerovo
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Krasnoyarsk
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Moscow
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Naberezhnye Chelny
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Novosibirsk
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Omsk
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Petrozavodsk
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Ryazan
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Smolensk
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: St.Petersburg
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Tomsk
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Ulan-Ude
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Vladivostok
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Yakutsk
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Yfa
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/2
city: Stavropol
country: Russian Federation
facility: Research Site
state: Nis-rru-xxx-2014/3
Study officials:
affiliation: AstraZeneca
name: Alexander Bedenkov
role: STUDY_DIRECTOR
affiliation: I.M. Sechenov First Moscow State Medical University
name: Vladimir Archipov, Prof.
role: PRINCIPAL_INVESTIGATOR
References: